S&P 500   2,996.95 (+0.03%)
DOW   26,837.86 (+0.19%)
QQQ   191.70 (-0.08%)
AAPL   242.43 (+1.03%)
MSFT   136.51 (+0.10%)
GOOGL   1,250.98 (+0.79%)
AMZN   1,753.04 (-0.72%)
CGC   21.12 (-0.14%)
NVDA   193.87 (-0.89%)
BABA   170.25 (+0.21%)
GE   9.04 (-0.22%)
TSLA   253.06 (-0.99%)
AMD   31.20 (-0.98%)
T   38.02 (-0.39%)
F   9.02 (-0.55%)
ACB   3.56 (-0.56%)
PRI   125.75 (-0.04%)
NFLX   271.78 (+1.91%)
BAC   31.25 (+0.16%)
GILD   65.98 (+0.18%)
S&P 500   2,996.95 (+0.03%)
DOW   26,837.86 (+0.19%)
QQQ   191.70 (-0.08%)
AAPL   242.43 (+1.03%)
MSFT   136.51 (+0.10%)
GOOGL   1,250.98 (+0.79%)
AMZN   1,753.04 (-0.72%)
CGC   21.12 (-0.14%)
NVDA   193.87 (-0.89%)
BABA   170.25 (+0.21%)
GE   9.04 (-0.22%)
TSLA   253.06 (-0.99%)
AMD   31.20 (-0.98%)
T   38.02 (-0.39%)
F   9.02 (-0.55%)
ACB   3.56 (-0.56%)
PRI   125.75 (-0.04%)
NFLX   271.78 (+1.91%)
BAC   31.25 (+0.16%)
GILD   65.98 (+0.18%)
Log in

Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

$98.69
+0.57 (+0.58 %)
(As of 10/23/2019 09:46 AM ET)
Today's Range
$98.00
Now: $98.69
$98.94
50-Day Range
$86.89
MA: $94.83
$101.84
52-Week Range
$64.72
Now: $98.69
$116.25
Volume12,239 shs
Average Volume665,161 shs
Market Capitalization$9.04 billion
P/E Ratio448.59
Dividend YieldN/A
Beta1.22
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$451.24 million
Cash Flow$0.51 per share
Book Value$5.30 per share

Profitability

Net Income$21.11 million

Miscellaneous

Employees585
Market Cap$9.04 billion
Next Earnings Date11/4/2019 (Confirmed)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Monday, July, 29th. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.24 by $0.13. The firm had revenue of $183.58 million for the quarter, compared to analyst estimates of $161.79 million. Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. The company's quarterly revenue was up 89.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.07) earnings per share. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Neurocrine Biosciences.

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for NBIX?

19 analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their forecasts range from $84.00 to $135.00. On average, they expect Neurocrine Biosciences' stock price to reach $106.56 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Has Neurocrine Biosciences been receiving favorable news coverage?

Headlines about NBIX stock have trended negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Neurocrine Biosciences.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a decrease in short interest in September. As of September 30th, there was short interest totalling 3,530,000 shares, a decrease of 7.6% from the August 30th total of 3,820,000 shares. Based on an average trading volume of 674,100 shares, the days-to-cover ratio is presently 5.2 days. Approximately 3.9% of the shares of the stock are short sold. View Neurocrine Biosciences' Current Options Chain.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.16%), Handelsinvest Investeringsforvaltning (0.05%), Envestnet Asset Management Inc. (0.04%), Assenagon Asset Management S.A. (0.03%), Virginia Retirement Systems ET AL (0.02%) and Brinker Capital Inc. (0.01%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Mission Wealth Management LP, Oakbrook Investments LLC and Fox Run Management L.L.C.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Richard F Pops. View Insider Buying and Selling for Neurocrine Biosciences.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Handelsinvest Investeringsforvaltning, Meeder Asset Management Inc., Envestnet Asset Management Inc., OmniStar Financial Group Inc., Heritage Investors Management Corp, Brinker Capital Inc. and Stephens Inc. AR. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $98.12.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $8.99 billion and generates $451.24 million in revenue each year. The company earns $21.11 million in net income (profit) each year or $0.22 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  797 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  1,050
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel